Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Medical Research Center, The Second Affiliated Hospital of Nantong University, Nantong, China.
Sci Rep. 2023 Apr 29;13(1):7043. doi: 10.1038/s41598-023-34027-9.
Clear cell renal cell carcinoma (ccRCC) is a main subtype of renal cancer, and advanced ccRCC frequently has poor prognosis. Many studies have found that lipid metabolism influences tumor development and treatment. This study was to examine the prognostic and functional significance of genes associated with lipid metabolism in individuals with ccRCC. Using the database TCGA, differentially expressed genes (DEGs) associated with fatty acid metabolism (FAM) were identified. Prognostic risk score models for genes related to FAM were created using univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses. Our findings demonstrate that the prognosis of patients with ccRCC correlate highly with the profiles of FAM-related lncRNAs (AC009166.1, LINC00605, LINC01615, HOXA-AS2, AC103706.1, AC009686.2, AL590094.1, AC093278.2). The prognostic signature can serve as an independent predictive predictor for patients with ccRCC. The predictive signature's diagnostic effectiveness was superior to individual clinicopathological factors. Between the low- and high-risk groups, immunity research revealed a startling difference in terms of cells, function, and checkpoint scores. Chemotherapeutic medications such lapatinib, AZD8055, and WIKI4 had better outcomes for patients in the high-risk group. Overall, the predictive signature can help with clinical selection of immunotherapeutic regimens and chemotherapeutic drugs, improving prognosis prediction for ccRCC patients.
透明细胞肾细胞癌(ccRCC)是肾癌的主要亚型,晚期 ccRCC 常预后不良。许多研究发现,脂质代谢影响肿瘤的发生和治疗。本研究旨在探讨与 ccRCC 患者脂质代谢相关的基因的预后和功能意义。使用 TCGA 数据库,鉴定与脂肪酸代谢(FAM)相关的差异表达基因(DEG)。使用单变量和最小绝对值收缩和选择算子(LASSO)Cox 回归分析,构建与 FAM 相关基因的预后风险评分模型。我们的研究结果表明,ccRCC 患者的预后与 FAM 相关 lncRNA(AC009166.1、LINC00605、LINC01615、HOXA-AS2、AC103706.1、AC009686.2、AL590094.1、AC093278.2)的谱密切相关。该预后标志物可作为 ccRCC 患者的独立预测指标。预测标志物的诊断效能优于单个临床病理因素。在低风险组和高风险组之间,免疫研究在细胞、功能和检查点评分方面显示出惊人的差异。拉帕替尼、AZD8055 和 WIKI4 等化疗药物对高风险组患者的疗效更好。总体而言,该预测标志物有助于临床选择免疫治疗方案和化疗药物,提高 ccRCC 患者的预后预测。